Merck & Co., Inc. (MRK)

Acerca de Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 53% of the company's 2025 sales were generated from US human health (pharmaceuticals and vaccines).

Al 3 de noviembre de 2026, la acción de Merck & Co., Inc. (MRK) bajó a $146.24, una baja de 1.43% (-$2.13) frente al cierre anterior. En la sesión, las acciones han operado entre $145.74 y $147.62. Eso ubica a MRK en el tercio superior de su rango de 52 semanas, de $82.01 a $156.92. Merck & Co., Inc. opera en el sector de pharmaceutical preparations y tiene una capitalización de mercado de aproximadamente $366.03 mil millones, con cerca de 706.3 mil acciones negociadas.

Últimas noticias de MRK

• What Could Derail Bristol Myers Squibb Stock?trefis.com· 3 nov, 9:12 a.m. ET
• Buy, Sell, or Hold? Tuesday’s Top Upgrades and Downgrades: AON, Bloom Energy, Chevron, Cloudflare, Marvell Technologies, Lumentum Holdings, Merck & Co., Roku, X-Energy, and More247wallst.com· 3 nov, 7:59 a.m. ET
• Merck Initiates Phase 3 Study Evaluating Ohtuvayre® (ensifentrine) for the Prevention of COPD Exacerbations in Adult Patients Receiving Standard of Care With a History of ExacerbationsYahoo Finance· 3 nov, 6:45 a.m. ETCOPDSOC
• How to Invest in the Rise of China’s Biotech: Buy U.S. Drug StocksYahoo Finance· 3 nov, 6:15 a.m. ET
• Merck to Divest CDMO Business to LonzaYahoo Finance· 3 nov, 1:45 a.m. ET
• Betting On Drug Sales: Is Viatris Or Lilly The Better Way In?trefis.com· 2 nov, 3:21 p.m. ET
• BTK Inhibitors Market to Expand During the Forecast Period (2026–2036) as Targeted Treatments Advance Across B-Cell Malignancies and Autoimmune Disorders | DelveInsightYahoo Finance· 2 nov, 1:00 p.m. ET
• Merck Stocks Decline With Higher Target Leaving a New-Launch Scale TestYahoo Finance· 2 nov, 11:45 a.m. ET

Fuente: Yahoo Finance RSS · Actualizado el 3 de noviembre de 2026

¿Quieres titulares, alertas e investigación con IA de MRK en un solo lugar? Crea una cuenta gratis →

• $MRK - Merck Initiates Phase 3 Study Evaluating Ohtuvayre® (ensifentrine) for the Prevention of COPD Exacerbations in Adult Patients Receiving Standard of Care With a History of Exacerbations

  @ripster47· 3 nov, 7:02 a.m. ET

• Did any investors believe the $MRK or $MRNA CEO about Intismeran? The paper below outlines how it will be another mRNA failure https://www.nature.com/articles/s43018-024-00794-1?error=cookies_not_supported&code=cd0c1e26-4cef-4fc9-8deb-37c2d16e280c

  @taxplanr· 3 nov, 6:47 a.m. ET· Bajista

• $IBRX and may the exec’s running $MRK rot in hell for doing nothing to improve the bcg supply whe they knew had shortage for 10 yrs while pushing keytruda for everyone except baldness!

  @TearsForFear· 2 nov, 4:28 p.m. ET

• #Biotechnology #Stocks Break Out To Leadership Position With Growth Mentions: $ABBV $GILD $LLY $MRK $IBB https://talkmarkets.com/article/biotechnology-stocks-break-out-to-leadership-position-with-growth

  @TalkMarkets· 2 nov, 3:16 p.m. ET

• $INO $MRK $PGEN $SLS Brokerage firms calling Retail Shorts to cover now or they will do a forced liquidation Cover after multiple attempts. Shorts 🔥 22,500,000 trapped. ✌️🙏❤️‍🩹

  @SellasgpsCurativeBAT11· 2 nov, 1:34 p.m. ET· Alcista

Fuente: Stocktwits. Las publicaciones de usuarios son opiniones, no hechos verificados. Ver lo que es tendencia →